martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Meta Platforms: From Heavy AI CapEx to 2026 ROI?

View original at finance.yahoo.com
Meta Platforms: From Heavy AI CapEx to 2026 ROI? This article first appeared on GuruFocus. This past year, Meta Platforms (NASDAQ:META) invested heavily in AI infrastructure, shaking Wall Street's near-term confidence…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lead-gen campaigns using Advantage+ show a 14% lower cost per lead than traditional campaigns

    80% confidence
  • Reels is running at a roughly $50 billion annualized revenue rate

    80% confidence
  • Instagram video consumption is up more than 30% year-over-year

    80% confidence
  • Meta has spent over $40 billion on R&D to date, with a significant portion allocated to AI/ML

    80% confidence
  • 2026 expenses will likely grow at a significantly faster rate than in 2025, largely due to infrastructure and personnel costs as new data center capacity comes online

    80% confidence
  • 2025 capital expenditures will exceed $70 billion, approximately 70% higher than in 2024

    80% confidence
  • Time spent on Facebook rose 5% in Q3 2025

    80% confidence
  • Threads usage jumped 10% in Q3 2025

    80% confidence
  • Advantage+ is handling over $60 billion in annual ad spend

    80% confidence
  • Average price per ad rose 10% year-over-year in Q3 2025, credited to AI

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com